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Background: Studies have shown in several diseases initially affecting podocytes, that the neighboring glomerular
parietal epithelial cells (PECs) are secondarily involved. The PEC response might be reparative under certain
circumstances, yet injurious under others. The factors governing these are not well understood. We have shown
that SM22α, an actin-binding protein considered a marker of smooth muscle differentiation, is upregulated in podocytes
and PECs in several models of podocyte disease. However, the impact of SM22α levels on PECs is not known.
Methods: Experimental glomerular disease, characterized by primary podocyte injury, was induced in aged-matched
SM22α +/+ and SM22α −/− mice by intraperitoneal injection of sheep anti-rabbit glomeruli antibody. Immunostaining
methods were employed on days 7 and 14 of disease.
Results: The number of PEC transition cells, defined as cells co-expressing a PEC protein (PAX2) and podocyte protein
(Synaptopodin) was higher in diseased SM22α −/− mice compared with SM22α +/+ mice. WT1 staining along Bowman’s
capsule is higher in diseased SM22α −/− mice. This was accompanied by increased PEC proliferation (measured by ki-67
staining), and an increase in immunostaining for the progenitor marker NCAM, in a subpopulation of PECs in diseased
SM22α −/− mice. In addition, immunostaining for vimentin and alpha smooth muscle actin, markers of epithelial-to-
mesenchymal transition (EMT), was lower in diseased SM22α −/− mice compared to diseased SM22α+/+ mice.
Conclusion: SM22α levels may impact how PECs respond following a primary podocyte injury in experimental
glomerular disease. Absent/lower levels favor an increase in PEC transition cells and PECs expressing a progenitor marker,
and a lower EMT rate compared to SM22α +/+ mice, where SM22 levels are markedly increased in PECs.
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Adult podocytes are terminally differentiated glomerular
epithelial cells that are unable to proliferate adequately
to replace those lost in glomerular diseases [1,2]. Re-
duced podocyte number leads to proteinuria and glo-
merulosclerosis in diabetic and non-diabetic glomerular
diseases [2-7]. The interplay between the parietal epithe-
lial cell (PECs) and visceral epithelial cell (podocyte) has
been keenly studied recently in experimental and human
glomerular diseases. Studies in humans, and in adoles-
cent PEC reporter mice, support a paradigm where PECs
function as local progenitors for podocytes [8-10]. In
normal human and rodent glomeruli, a subset of PECs* Correspondence: stuartjs@ u.washington.edu
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unless otherwise stated.co-express proteins considered unique to both podo-
cytes, and to PECs [8,9,11-14]. Some have called these
transitional cells [8,11-14]. Moreover, a subset of PECs
in humans and rodents express proteins considered as
general markers for stem/progenitor cells, suggesting the
possibility that a renal progenitor system exists [15]. Re-
cent studies in mice have disputed this concept [16-19].
Two lines of evidence suggest that rather than PECs be-
ing regenerative, PECs augment glomerular damage fol-
lowing podocyte injury. First, their activation as evidenced
by the de novo expression of CD44 likely contributes to
disease progression by augmenting scarring and crescent
formation under certain circumstances [20,21]. Second, in
response to injury PECs can also undergo epithelial-to-
mesenchymal transition (EMT) [22-27], which is a pheno-
typic change characterized by loss/decrease of epithelial
characteristics while attaining features of mesenchymaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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types” (i.e. progenitors, activated-CD44 positive, EMT) are
not mutually exclusive.
The mechanisms associated with PEC EMT are not well
defined. SM22α, also known as transgelin, is a 22-kDa
actin-binding protein of the calponin family, a cytoskel-
eton associated protein and one of the earliest markers of
smooth muscle differentiation [28,29]. Although SM22α is
absent in normal glomeruli, it is markedly increased in dis-
eased glomeruli, in both podocytes and PECs [30-32]. The
kidneys of SM22α-deficient mice develop normally and
appear similar to wildtype mice histologically [33]. How-
ever, we and others have shown that SM22α staining is
markedly increased in experimental animal models of
membranous nephropathy (PHN model), FSGS (PAN,
ADR nephropathy, obesity-related glomerulopathy), cres-
centic glomerulonephritis (anti-GBM nephritis model),
mesangial proliferation (anti-Thy1 model) and obstructive
nephropathy (UUO model) [27,30,31,34-39]. In these
studies, de novo SM22α expression was detected in
podocytes, as well as in PECs. When experimental cres-
centic glomerulonephritis was induced, SM22α+/+
mice had more severe glomerular disease compared to
SM22α −/− mice, marked by greater podocyte apop-
tosis, lower podocyte number, more proliferation, and
increased activation of Erk1/2 [32], indicating SM22α
likely plays a deleterious role in podocytes.
The focus of these earlier studies was on SM22α and the
podocyte [32,34-36]. Since then, interest in PECs has in-
creased substantially, enhancing our understanding of this
less well defined glomerular epithelial cell [21,22,40,41].
Accordingly, in the current experiments, we studied the
potential biological affect of SM22α on PECs in experi-
mental glomerular disease, with a focus on glomerular epi-
thelial transition cells and EMT.
Methods
Passive nephrotoxic models of experimental crescentic
glomerulonephritis
SM-CreERT2(ki) transgenic mice were used, which have
been extensively characterized previously [32]. We have
also previously reported that giving these mice sheep anti-
glomerular antibody used in this study leads to passive
nephrotoxic crescentic glomerulonephritis, with varying
degrees of capillary loop dilatation, mesangial expansion,
crescent formation with increased WT-1 and Ki-67 stain-
ing in the glomerular tuft [32,42]. Please not that this is
not the same antibody used to induce an experimental
model of classic FSGS, which we have reported is charac-
terized by reduced podocyte number and an absence of
glomerular epithelial cell proliferation [11,13,14,43].
The passive nephrotoxic nephritis model was induced
in male SM22α wildtype (+/+) and null (−/−) mice, aged
12 wk, by intraperitoneal injection of sheep anti-rabbitglomeruli antibody [12. 5 mg/20 g body weight 2 doses
at days 0 and 3]. These mice were randomly assigned
into the following groups: day 0 (n = 6 +/+ and −/−
mice), day 7 (n = 10, +/+ and −/− mice) and day 14 (n =
5 +/+ and −/− mice). The sheep anti-rabbit glomeruli
antibody was produced by immunizing sheep with whole
rabbit glomeruli, as previously described [42]. Control
animals did not receive the sheep anti-rabbit glomeruli
antibody. The animal care committee of the University
of Washington, School of Medicine reviewed and ap-
proved the experimental protocol and animal procedures




To identify and quantitate the number of glomerular
epithelial cells that express both a podocyte and PEC
proteins (called glomerular epithelial transition cells),
double immunostaining was performed as follows. Indir-
ect immunofluorescence was performed on 4 um-thick
section kidney biopsies fixed in formalin and embedded
in paraffin as we have previously reported [12-14,32,43].
In brief, paraffin was removed using Histoclear (National
Diagnostics, Atlanta, Ga., USA), and sections were rehy-
drated in ethanol. Antigen retrieval was performed by
boiling sections in the microwave in 1 mM EDTA,
pH 6.0. Nonspecific protein binding was blocked with
background buster (Accurate Chemical & Scientific,
Westbury, NY, USA) and endogenous biotin activity was
quenched with the Avidin/biotin blocking kit (Vector
Laboratories, Burlingame, CA, USA). After the blocking
steps described above, tissue sections were incubated over-
night at 4°C with the primary antibodies. The following
primary antibodies were used: rabbit anti-rat paired box
gene 2 (PAX2, a PEC nuclear protein) polyclonal antibody
diluted 1:500 (Zymed Laboratories, South San Francisco,
Calif., USA) and mouse anti- Synaptopodin (Synpo, a
podocyte protein) monoclonal antibody, diluted 1:10
(Fitzgerald). The appropriate biotinylated secondary anti-
body (Vector Laboratories) was applied followed by Strep-
tavidin, AlexaFluor 594 conjugate and Alexa 488 conjugate.
Identifying podocyte and potential PEC progenitors
The rabbit anti-WT-1 polyclonal antibody (Santa Cruz
Biotechnology, USA), and NCAM ( Millipore, MA,
USA) were used to identify podocyte and potential PEC
progenitors . Positive cells being a bluish-gray color were
visualized with the Vector SG substrate kit (Vector).
Identifying EMT
Indirect immunoperoxidase immunostaining was per-
formed for PAX2 as described above, in combination
with vimentin (1:100 Santa Cruz, CA, USA) and alpha-
Naito et al. BMC Nephrology 2014, 15:174 Page 3 of 11
http://www.biomedcentral.com/1471-2369/15/174smooth muscle actin (α-SMA, 1:400 Abcam, UK).).
Omission of the primary antibody was used as a nega-
tive control. Vimentin and α-SMA staining were visu-
alized with the Vector SG substrate kit; positive cells
are bluish-gray color (Vector). Blocking steps were
performed following SG substrate color development.
Because α-SMA and PAX2 antibody were developed in
rabbits, an anti-rabbit IgG antibody Fab fragment
(Jackson ImmunoResearch, West Grove, PA, USA)
was used to saturate all the binding sites created dur-
ing the first set of staining. In addition, peroxidase ac-
tivity derived from the first set of staining was also
blocked using alkaline phosphatase/horseradish perox-
idase block (SurModics, MN, USA). Next, a second set
of staining was performed for PAX2. A rabbit-on-
rodent AP-polymer kit (Biocare Medical, CA, USA)
was used for additional blocking and substitutive sec-
ondary antibody according to the manufacturer`sFigure 1 PECs number in SM22 null mice is higher with experimental
images of PAX2 staining (red) at × 630 original magnification. SM22α +/+ is
14. PECs are on Bowman’s capsule (arrow) and in tuft (arrow head). B) Num
(mm) is increased in SM22α −/− mice, compared with SM22α +/+ mice. C) Nu
SM22α −/+ −mice, compared with SM22α +/+ mice.protocol. Staining was visualized with the Warp Red
chromogen kit, red color (Biocare Medical).
Measuring proliferation
To quantitate changes in PEC proliferation in SM22α
mice rabbit anti-Ki-67 monoclonal antibody (Thermo
Fisher Scientific, Fremont, Calif., USA) were used to
identify proliferating cells. Both of them were visual-
ized with the Vector SG substrate kit, with positive
cells being a bluish-gray color (Vector). For all stains,
negative controls consisted of omitting the primary
antibodies.
Staining quantitation and statistical analysis
Quantification of positively stained cells was per-
formed on individual animals at each time point using
a combination of bright-field and fluorescent micros-
copy as we have reported [12-14]. The mean numberglomerular disease compared to wildtypes. A) Representative
A1-A3. SM22α −/− is A4-A6. A1, A4: day 0. A2, A5: day 7. A3, A6: day
ber of PAX2 positive cell along BBM / Bowman’s capsule (BC) length
mber of PAX2 positive cells in tuft area / tuft area (mm2) is increased in
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mal. Because of known changes in glomerular size with
aging and weight increasing, ImageJ software was used
to measure the length of the Bowman’s basement
membrane and glomerular tuft area according to ‘The
ImageJ User Guide’ (version 1.44) as we described pre-
viously [12-14]. These measures were then used as de-
nominators for the number of positively stained
podocytes, and double-stained cells along Bowman’s
capsule and in tuft, respectively.
Oneway ANOVA with unpaired t-test was calculated
and a p-value below 0.05 was considered significant. The
quantitative analyses of Bowman’s capsule length and tuft
area were evaluated by ImageJ. All values are means +/−
SEM. Statistical significance was evaluated using StatFlex
version 6 (Artech Co., Ltd., Osaka, Japan).Figure 2 Transition cells in SM22 null mice are higher with experimen
images of transition cells at × 630 original magnification. Glomerular epithe
cytoplasmic) double positive cells. SM22α +/+ is A1-A9. SM22α −/− is A10-
A16-A18) were reacted anti PAX2 antibody (Ab) (A1, A4, A7, A10, A13, A16)
images were merged (A3, A6, A9, A12, A15, A18). The glomerular transition
Number of glomerular epithelial transition cells along BBM / Bowman’s cap
SM22α +/+ mice. C) Number of glomerular epithelial transition cells in tuft
with SM22α +/+ mice.Results
PEC number is higher in SM22 null mice with experimental
glomerular disease compared to SM22 wildtype mice
To determine PEC number, PAX2 staining was per-
formed and quantitated (Figure 1). Because of potential
changes in glomerular size during disease, the length of
Bowman’s capsule, measured in millimeters, was used as
the denominator. PEC number was expressed as the
number of PAX2 positive cells/Bowman’s capsule length
in millimeters (Figure 1B). There was no statistical sig-
nificance difference in PEC number at baseline between
normal SM22α +/+ and SM22α −/− mice (9.19 ± 0.93 vs.
13.58 ± 1.26 PAX2 positive cells per mm of Bowman’s
capsule; P =0.08). However, in experimental glomerular
disease, PEC number was higher than baseline, and
SM22α −/− mice had a higher number of PECs comparedtal glomerular disease compared to wildtypes. A) Representative
lial transition cells defined PAX2 (red, nuclear) and SYNPO (green,
A18. Day 0 (A1-A3, A10-A12), day 7 (A4-A6, A13-A15), day 14 (A7-A9,
and anti Synaptopodin (SYNPO) Ab (A2, A5, A8, A11, A14, A17). The
cells are on Bowman’s capsule (arrow) and in tuft (arrow head). B)
sule (BC) length (mm) is increased in SM22α −/− mice, compared with
area / tuft area (μm2) is increased in SM22α −/+ −mice, compared
Figure 3 NCAM staining in SM22 null mice is higher with experimental glomerular disease compared to wildtypes. A) Representative
images of NCAM staining (brown) at × 630 original magnification. SM22α +/+ is A1-A3. SM22α −/− is A4-A5. A, D: day 0. B, E: day 7. C, F: day 14.
B) % of NCAM positive area in glomeruli is increased in SM22α −/− mice, compared with SM22α +/+ mice.
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PAX2+ cells/Bowman’s capsule length in mm, P <0.01),
and at day 14 (23.92 ± 1.14 vs. 38.55 ± 1.18; P <0.01)
(Figure 1B).
Because staining for PEC proteins have been detected in
cells within the glomerular tuft, [8,9,12-14], the number of
PAX2 positive cells was also measured in the tuft,
expressed per mm2 area. Very few PAX2 positive cells
were in the tuft at baseline in SM22α +/+ and SM22α −/−
mice (12.66 ± 6.24 PAX2+ cells/mm2 of glomerular tuft
vs.10.08 ± 6.60; P = 1.00). However, in experimental glom-
erular disease, the number of PAX2 positive cells in theFigure 4 WT1 staining along Bowman’s capsule in SM22α −/− mice is
images of WT1 staining (blue/gray) at × 630 original magnification. SM22α
day 14. Allows are WT1 positive cells. B) Number of WT1 positive cells along B
compared with SM22α +/+ mice.tuft increased, but was significantly higher in SM22α −/−
mice compared to SM22α +/+ mice at day 14 (303.13 ±
41.07 vs. 576.51 ± 55.52; P <0.01) (Figure 1C). The trend
was also higher in SM22 −/− mice at day 7, but did not
reach statistical significance (225.27 ± 29.00vs. 331.59 ±
27.79; P =0.126).
Transition cells in SM22 null mice are higher with
experimental glomerular disease compared to wildtypes
Double immunofluorescent staining for PAX2 (PEC
marker) and synaptopodin (podocyte marker) was
performed to determine the number of glomerularhigher with experimental glomerular disease. A) Representative
+/+ is A1-A3. SM22α −/− is A4-A6. A1, A4: day 0. A2, A5: day 7. A3, A6:
BM / Bowman’s capsule (BC) length (mm) is increased in SM22α −/− mice,
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within the glomerular tuft (Figure 2). At baseline, very
few PAX2+/Synaptopodin+ cells were detected along
Bowman’s capsule in normal SM22α +/+ mice or −/−
mice (0.15 ± 0.04 vs. 0.18 ± 0.05 PAX2+/Synaptopodin+
cells/mm of Bowman’s capsule, P =1.00). The number of
transition cells along Bowman’s capsule increased signifi-
cantly in both strains with experimental glomerular dis-
ease, although the magnitude of increase was greater in
SM22α −/− mice at day 7 (6.35 ± 0.34 vs. 4.79 ± 0.28
PAX2+/Synaptopodin+ cells/mm of Bowman’s capsule,
P <0.01 vs. +/+), and day 14 (8.38 ± 0.60 vs. 6.56 ± 0.46,
P <0.05 vs. +/+) (Figure 2B).
Transition cells that were barely detected in the
glomerular tuft at baseline in SM22α +/+ or −/− mice
(13.19 ± 3.09, vs. 23.53 ± 5.95 PAX2+/Synaptopodin+ cells/
mm2 of glomerular tuft; P = 1.00 ), increased in glomerular
disease. The number of transition cells increased in
SM22α −/− mice with disease at day 7 (324.89 ± 21.20 vs.
219.82 ± 16.07, P <0.01 vs. +/+), and at day 14 (951.32 ±
67.17 vs. 326.41 ± 26.33, P <0.01 vs. +/+) (Figure 2C).
These data show that the number of glomerular transi-
tion cells along Bowman’s capsule and in the glomerular
tuft was higher in diseased SM22 −/− mice compared to
diseased SM22 +/+ mice.
NCAM staining in SM22 null mice is higher with
experimental glomerular disease compared to wildtypes
Neural cell adhesion molecule (NCAM) staining was used
to identify potential PEC progenitors, similar to that de-
scribed by Benigni (Figure 3A) [44]. At baseline, occasional
NCAM staining was detected in cells lining Bowman’sFigure 5 Proliferation is higher along Bowman’s capsule in experimen
Immunohistochemistry of Ki67 (blue/gray). SM22α +/+ is A1-A3. SM22α −/−
Ki67 positive cells along BBM / Bowman’s capsule (BC) length (mm) is increcapsule in normal SM22α +/+ and −/− mice (0.87 ± 0.03
vs. 0.88 ± 0.03; P =1.00). NCAM staining increased in
glomerular disease, but was higher in SM22 −/− mice
at day 7 (1.88 ± 0.06 vs. 1.61 ± 0.05, P <0.01 vs. +/+)
and at day 14 (2.73 ± 0.14 vs. 2.03 ± 0.06,. P <0.01
vs. +/+) (Figure 3B). NCAM staining localized to PEC
predominantly.
WT1 staining along Bowman’s capsule is higher in SM22
null mice with disease
WT-1 staining has traditionally been used as a marker
to identify podocytes [45], WT-1 staining was barely de-
tected along Bowman’s capsule in SM22α +/+ and −/−
mice at baseline (0.00 ± 0.00 vs. 0.09 ± 0.04; P = 0.52)
(Figure 4). However, in experimental glomerular disease,
the number of WT-1 positive cells along Bowman’s cap-
sule was higher in SM22α −/− mice at day 7 (1.70 ± 0.16
vs. 0.70 ± 0.09, P <0.01 vs. +/+), and at day 14 (2.12 ±
0.26 vs. 0.67 ± 0.12, P <0.01 vs. +/+). Thus, similar to
other studies [9,11-14,40,46] WT-1 staining is increased
in cells lining Bowman’s capsule in mice with disease,
and is higher SM22 −/− mice.
Proliferation is higher in diseased SM22 null mice
Ki-67 immunostaining, a proliferation marker [47],
was barely detected along the Bowman’s capsule at
baseline in SM22α +/+ and −/− mice (0.07 ± 0.04 vs.
0.06 ± 0.03 positive cells/Bowman’s capsule length; P =
1.00) (Figure 5A1 & A4). Although the number in-
creased in diseased SM22α +/+ mice, the number of
Ki-67 cells along the Bowman’s capsule was higher in
diseased SM22α −/− mice at day 7 (0.31 ± 0.05 vs. 0.77 ±tal glomerular disease in SM22 null mice. A)
is A4-A6. A1, A4: day 0. A2, A5: day 7. A3, A6: day 14. B) Number of
ased in SM22α −/− mice, compared with SM22α +/+ mice.
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P <0.01) (Figure 5A2, A3, A5, A6). These data show that a
subset of cells along Bowman’s capsule proliferate in dis-
ease, more so in SM22α −/− mice than SM22α +/+ mice
(Figure 5B).
Double staining for Ki-67 and PAS was performed to
evaluate proliferating cells in crescents (Figure 6A). In
SM22α +/+ mice at day 7, 15.36 ± 1.46% of glomeruli
contained crescents. SM22α −/− mice with disease had
fewer crescents at day 7 (10.17 ± 1.19% vs. 15.36 ± 1.46%;
P <0.05 vs. +/+) (Figure 6B). The percentage of crescents
with Ki67+ demonstrate no significant difference between
SM22α +/+ and SM22α −/− mice at day 7(87.93 ± 6.75%
vs. 85.15 ± 10.24%, P = 1.00), and at day 14 (38.50 ± 15.02%
vs. 52.69 ± 7.50%, P = 0.15). Ki-67 staining was used as a
marker of cell proliferation (Figure 6C). Similar to the re-
sults shown above, the percentage of glomeruli with cells
staining for Ki67 that were along Bowman’s capsule but
not within a crescent was higher in SM22α −/− comparedFigure 6 The crescent is higher in diseased SM22α +/+ mice. A) Repre
magnification. SM22α +/+ is A1-A3. SM22α −/− is A4-A6. A1, A4: day 0. A2,
heads are Ki67+ cells on Bowman’s capsule (BC). B) % glomeruli of crescen
Ki67+ cells outside of crescents on Bowman’s capsule (BC) / all glomeruli.to SM22α +/+ at day 7 (17.66 ± 1.12 vs. 14.65 ± 0.43; P =
0.32) and at day 14 (22.1 ± 1.00 vs. 15.83 ± 0.79, P <0.05)
(Figure 6D).
Epithelial-to-mesenchymal transformation of PECs is
lower in disease in SM22 null mice with experimental
glomerular
Epithelial-to-mesenchymal transformation (EMT) has
been reported in PECs in disease, and correlates with
worse outcomes [25,48]. In order to determine if the levels
of SM22α affected PEC EMT, PAX2 (used as a PEC
marker) was double-stained with classic EMT markers
α-smooth muscle actin (α-SMA) or vimentin (Figure 7).
α-SMA+PAX2+ double positive cells were very occasion-
ally detected along Bowman’s capsule in SM22α +/+ and
SM22α −/− mice at baseline (0.03 ± 0.02 vs. 0.04 ± 0.02;
P = 1.00). At day 7, the number of α-SMA+PAX2+ double
positive cells was higher in SM22+/+ mice (0.32 ± 0.05 vs.
0.10 ± 0.03; P = <0.01 vs. −/−). The number of α-SMAsentative images of Ki67 staining (blue/gray) at × 630 original
A5: day 7. A3, A6: day 14. Allows are Ki67+ cells in crescents. Allow
t. C) % crescent within Ki-67+ cells / all crescents. D) % glomeruli with
Figure 7 Double positive cells for PAX2 and α-SMA at × 630 original magnification. A) Double positive cells for PAX2 (red, nuclear) and α-SMA
(blue/gray, cytoplasmic) at × 630 original magnification. A1-A3: representative images of PAX2/α-SMA double staining at × 630 original magnification in
SM22α +/+ mice. A4-A6: fluorescent microscopic view of the A1-A3 bright-field view, where only PAX2 staining is seen because only the warp-red
substrate is visible by fluorescent microscopy. A7-A9: representative images of PAX2/α-SMA double staining at × 630 original magnification in SM22α −/−
mice. A10-A12: fluorescent microscopic view of the A7-9 bright-field view, where only PAX2 staining is seen because only the warp-red substrate is visible
by fluorescent microscopy. A1, A4, A7, A10: day 0. A2, A5, A8, A11: day 7. A3, A6, A9, A12: day 14. B) Number of double positive cells for PAX2 and α-SMA
along BBM/Bowman’s capsule (BC) length (mm) is increased in SM22α −/−mice, compared with SM22α +/+ mice.
Naito et al. BMC Nephrology 2014, 15:174 Page 8 of 11
http://www.biomedcentral.com/1471-2369/15/174+PAX2+ double positive cells was even higher at day 14 in
SM22α +/+ mice compared to SM22α −/− mice (1.38 ±
0.17 vs. 0.30 ± 0.07; P <0.01 vs. −/−) (Figure 7).
Double staining for vimentin and PAX2, was barely de-
tected along Bowman’s capsule at baseline in SM22α +/+
and −/− mice (0.03 ± 0.02 vs. 0.03 ± 0.02; P =1.00). The
number of vimentin+PAX2+ double positive cells along the
Bowman’s capsule was higher in SM22α +/+ mice at day 7
(2.10 ± 0.20 vs. 3.39 ± 0.27; P <0.01 vs. −/−) and day 14
(2.38 ± 0.32 vs. 4.57 ± 0.44; P <0.01 vs. −/−) (Figure 8).
These data show that two markers of EMT are signifi-
cantly higher in PECs in SM22 wildtype mice compared
to null mice with disease.
Discussion
Studies in man show that PECs might play a critical role
in glomerular repair through their progenitor function
[8,9,15,21]. However, PECs might paradoxically contrib-
ute to the deterioration of glomerular function by aug-
menting scarring and crescent formation under certain
circumstances in man and mouse [21]. The precise mecha-
nisms underlying this dichotomy are poorly understood.Because SM22α was markedly increased in PECs (and
podocytes) in diseases considered primarily podocyte in
nature [27,30,31,34-39], the purpose of the current studies
was to determine if the levels of SM22 had any affect on
certain PEC properties in response to primary injury to
podocytes.
The first major finding was that in experimental glom-
erular disease, there was a direct association between re-
duced SM22 levels and increased PEC number, including
an increase in the PEC transition cell subpopulation. The
latter was supported by a higher number of cells co-
staining for a PEC protein, and two podocyte proteins,
namely synapotopodin and WT-1. Moreover, there is a
subset of PECs along Bowman’s capsule that have in-
creased expression for NCAM. NCAM expression has
been shown in metanephric mesenchyme and in the glom-
erular capsule in the mature kidney [49,50]. Others have
shown that NCAM is a marker of renal progenitor cells
[44,51]. This suggests, but does not prove, that the sub-
population of PECs that might acquire a progenitor
phenotype in disease is higher in the absence of SM22.
Given that studies have shown that reduced SM22α
Figure 8 Double positive cells for PAX2 (red) and vimentin at × 630 original magnification. A) Double positive cells for PAX2 (red, nuclear)
and vimentin (blue gray, cytoplasmic) at × 630 original magnification. A1-A3: representative images of PAX2/vimentin double staining at × 630
original magnification in SM22α +/+ mice. A4-A6: fluorescent microscopic view of the A1-A3 bright-field view, where only PAX2 staining is seen
because only the warp-red substrate is visible by fluorescent microscopy. A7-A9: representative images of PAX2/vimentin double staining at × 630
original magnification in SM22α −/− mice. A10-A12: fluorescent microscopic view of the A7-A9 bright-field view, where only PAX2 staining is seen
because only the warp-red substrate is visible by fluorescent microscopy. A1, A4, A7, A10: day0. A2, A5, A8, A11: day 7. A3, A6, A9, A12: day 14.
B) Number of double positive cells for PAX2 and vimentin along BBM / Bowman’s capsule (BC) length (mm) is increased in SM22α −/− mice,
compared with SM22α +/+ mice.
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muscle cells and prostate tumor cells [52,53], and that
SM22 levels were significantly reduced in proliferating
cells in prostate, lung, breast, gliobrastoma and colorec-
tal cancers [54-56], it is perhaps not surprising that
PECs had higher proliferation in mice deficient in
SM22α.
A second major finding in the current study was that
although epithelial-to-mesenchymal transition (EMT)
occurred in both strains of mice with disease, the mag-
nitude of EMT was higher in SM22 +/+mice compared
to SM22 −/− mice, judged by the EMT markers alpha
smooth muscle actin and vimentin. EMT in kidney
and non-kidney cell types has been associated with fi-
brosis, and is therefore considered undesirable [57].
Indeed, studies have previously demonstrated EMT in
PECs. Studies by Yee-Yung [23] and Shimizu [58]
showed that PEC EMT was deleterious. In contrast,
Swetha showed that EMT plays a role in plasticity of
cultured PECs [26], which is considered beneficial. In
the current study our data supports a notion that PECEMT is significantly lower in mice lacking SM22α.
One might the current data that the lower PEC EMT
in null mice with disease is consistent with an overall
improved outcome.
Several limitations to this manuscript are noted, al-
though they do not substantially impact the enthusiasm
for the findings. First, although mice with genetically
altered SM22 level are used, this is largely descriptive.
Second, an alternate explanation to both major findings
is that they are independent from SM22 levels, because
the podocyte lesion is worse in null mice. Regardless,
this is informative, because the latter explanation
would suggest that the degree of PEC response corre-
lates with the degree of podocyte damage. One might
even argue that the differences in the PEC responses
are due to differences in the immune response to injury
between the null and wildtype strains used. Please note
that although the data was not shown, there were no
differences between the two mouse strains in the
amount of disease-inducing antibody deposited in podo-
cytes (it does not deposit in PECs). We have previously
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http://www.biomedcentral.com/1471-2369/15/174reported that this model is not characterized by an inflam-
matory cell response, which makes this an unlikely con-
tributor to underlie any differences between SM22 −/−
and +/+ mice.
Conclusions
PECs are increasingly being recognized as second re-
sponders following a primary injury to neighboring podo-
cytes. On one hand, the secondary response by PECs
might be reparative if they indeed are a source of podocyte
progenitors. The data from the current study suggests that
they do express a putative progenitor marker (NCAM),
and that the number of transition cells is increased. These
events are augmented in the absence of SM22α. On the
other hand, the secondary response by PECs can be dele-
terious if they are activated to express CD44 or undergo
EMT. Our data shows that PEC EMT is reduced in mice
lacking SM22α. Taken together, the current data support a
model that when PECs are unable to express (or increase)
SM22α in a model of podocyte injury, they tend to favor a
less injurious response judged by enhanced progenitor
markers and less EMT. Further studies are needed to bet-
ter delineate these pathways and to provide functional
proof of this concept.
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